FDA Granted Fast Track Designation for Genervon’s Breakthrough Biotechnology Multi-Target #ALS Drug GM604 Expediting Drug Approval Process | #ALS AWARENESS #LouGehrigsDisease #PARKINSONS | Scoop.it
From www.heraldonline.com - June 27, 2013 10:23 PM
In a huge victory for ALS sufferers, FDA granted Genervon Biopharmaceuticals a fast track designation for its first in class highly effective multi-target master regulator biotechnology drug GM604 for ALS.